文献速递MDS 与骨髓增殖性肿瘤白血病

慢性中性粒细胞白血病:2018年诊断、分子遗传学与管理更新

Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
PubMed 文献 · Am J Hematol · 2018-01-01

慢性中性粒细胞白血病(CNL)是一种潜在侵袭性骨髓增殖性肿瘤,2016年WHO分类将CSF3R体细胞激活突变(最常见CSF3RT618I)纳入诊断标准,使多数疑似病例可通过分子检测准确诊断;SETBP1和ASXL1等并发突变常见且似乎具有预后意义,但CNL的罕见性延迟了对完整分子发病机制和个体预后的全面理解。

要点

  • WHO诊断标准:白细胞≥25×10⁹/L且≥80%为中性粒细胞,循环中性粒细胞前体<10%,原始细胞罕见,无发育异常及其他骨髓增殖性肿瘤标准。
  • 2016年WHO分类将CSF3R体细胞激活突变(最常见CSF3RT618I)列为诊断依据,使多数疑似病例可通过分子检测准确诊断。
  • SETBP1和ASXL1等并发突变常见且似乎具有预后意义,但CNL罕见延迟了对完整分子发病机制和个体预后的全面理解。

核心结论

  • 2016年WHO分类将CSF3R体细胞激活突变(最常见CSF3RT618I)纳入诊断标准,使多数疑似CNL病例可通过分子检测准确诊断。
  • CSF3R突变是原发驱动突变,解释其特征性临床表型及对分子靶向治疗的潜在易感性。
  • SETBP1和ASXL1等并发突变常见且似乎具有预后意义,但CNL的罕见性延迟了对完整分子发病机制和个体预后的全面理解。

研究设计与样本

  • 综述:2018年更新,汇总CNL的诊断标准、分子遗传学与管理进展。

主要发现

  • 当前WHO诊断标准包括白细胞≥25×10⁹/L且≥80%为中性粒细胞,循环中性粒细胞前体<10%,原始细胞罕见,无发育异常及其他骨髓增殖性肿瘤的临床或分子标准。
  • 既往CNL诊断常为排除性诊断,基于符合上述标准患者无可识别的生理性中性粒细胞增多原因。
  • 2016年WHO分类将CSF3R体细胞激活突变(最常见CSF3RT618I)列为诊断依据,使多数疑似病例可通过分子检测准确诊断。
  • CSF3R突变是原发驱动突变,解释其特征性临床表型及对分子靶向治疗的潜在易感性。
  • SETBP1和ASXL1等并发突变常见且似乎具有预后意义,但CNL的罕见性延迟了对完整分子发病机制和个体预后的全面理解。

关键数值与推荐

  • WHO诊断标准:白细胞≥25×10⁹/L且≥80%为中性粒细胞,循环中性粒细胞前体<10%,原始细胞罕见,无发育异常及其他骨髓增殖性肿瘤标准。
  • 2016年WHO分类将CSF3R体细胞激活突变(最常见CSF3RT618I)列为诊断依据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • CNL的罕见性延迟了对完整分子发病机制和个体预后的全面理解。
  • 关于全基因组图谱的数据仍在发展中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW AND DIAGNOSIS: Chronic neutrophilic leukemia (CNL) is a potentially aggressive myeloproliferative neoplasm, for which current WHO diagnostic criteria include leukocytosis of ≥ 25 x 109 /L of which ≥ 80% are neutrophils, with < 10% circulating neutrophil precursors with blasts rarely observed. In addition, there is no dysplasia, nor clinical or molecular criteria for other myeloproliferative neoplasms. UPDATE ON DIAGNOSIS: Previously the diagnosis of CNL was often as one of exclusion based on no identifiable cause for physiologic neutrophilia in patients fulfilling the aforementioned criteria. The 2016 WHO classification now recognizes somatic activating mutations of CSF3R (most commonly CSF3RT618I) as diagnostic, allowing for an accurate diagnosis for the majority of suspected cases through molecular testing. These mutations are primary driver mutations, accounting for the characteristic clinical phenotype and potential susceptibility to molecularly targeted therapy. RISK STRATIFICATION: Concurrent mutations, common to myeloid neoplasms and their precursor states, most frequently in SETBP1 and ASXL1, are frequent and appear to be of prognostic significance. Although data are evolving on the full genomic profile, the rarity of CNL has delayed complete understanding of its full molecular pathogenesis and individual patient prognosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Elliott MA, Tefferi A. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management. Am J Hematol. 2018. PMID: 29512199. doi:10.1002/ajh.24983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。